Treated with Ro5-3335, a RUNX1-CBFβ interaction inhibitor, the level of p-FOXO1Ser256 and Bcl-2 were significantly changed in control cancer cell lines (SKOV3, OVCAR3), meanwhile the expression level of FOXO1 was almost unchanged after Ro5-3335 treatment (Fig. 4G–H, Additional file 1: Fig. S3C–D). The gene discussed is BCL2; the disease is cancer.